Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry.

[1]  P. Ponikowski,et al.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. , 2006, European heart journal.

[2]  R. Touyz,et al.  Adipocytes Produce Aldosterone Through Calcineurin-Dependent Signaling Pathways: Implications in Diabetes Mellitus–Associated Obesity and Vascular Dysfunction , 2012, Hypertension.

[3]  Akshay S. Desai,et al.  Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.

[4]  S. Solomon,et al.  Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction , 2018, American journal of hypertension.

[5]  M. Banach,et al.  Leptin, cardiovascular diseases and type 2 diabetes mellitus , 2018, Acta Pharmacologica Sinica.

[6]  L. Lund,et al.  The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure , 2018, Upsala journal of medical sciences.

[7]  C. Fava,et al.  Prevalence and Comorbidities of Resistant Hypertension: A Collaborative Population-Based Observational Study , 2018, High Blood Pressure & Cardiovascular Prevention.

[8]  C. Thakar,et al.  Adherence to Antihypertensive Agents and Blood Pressure Control in Chronic Kidney Disease , 2010, American Journal of Nephrology.

[9]  L. Weinrauch,et al.  MICROVASCULAR COMPLICATIONS — NEPHROPATHY ( B ROSHAN , 2014 .

[10]  Nancy M Albert,et al.  Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.

[11]  David A Calhoun,et al.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. , 2018, Hypertension.

[12]  Thomas Kahan,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[13]  U. Dahlström,et al.  Heart failure registry: a valuable tool for improving the management of patients with heart failure , 2010, European journal of heart failure.

[14]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[15]  L. Ruilope,et al.  Resistant hypertension: new insights and therapeutic perspectives. , 2019, European heart journal. Cardiovascular pharmacotherapy.

[16]  L. Igel,et al.  Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment , 2013, Journal of clinical hypertension.

[17]  H. Ross,et al.  Prognostic value of blood pressure in ambulatory heart failure: a meta-analysis and systematic review. Ambulatory blood pressure predicts heart failure prognosis , 2021, Heart Failure Reviews.

[18]  D. Kitzman,et al.  The pathogenesis of acute pulmonary edema associated with hypertension. , 2001, The New England journal of medicine.

[19]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[20]  T. Cascino,et al.  Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction , 2017, Current Hypertension Reports.

[21]  T. Tsujimoto,et al.  Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension , 2020, Journal of the American Heart Association.

[22]  C. Yancy,et al.  Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction , 2018, JAMA cardiology.

[23]  Heather M. Tavel,et al.  Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.

[24]  J. Sun,et al.  The Prevalence and Prognosis of Resistant Hypertension in Patients with Heart Failure , 2014, PloS one.

[25]  J. Lima,et al.  Early Onset Hypertension Is Associated With Hypertensive End-Organ Damage Already by MidLife. , 2019, Hypertension.

[26]  B. Davis,et al.  Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease: Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2014, Hypertension.

[27]  Takeshi Kimura,et al.  Admission systolic blood pressure as a prognostic predictor of acute decompensated heart failure: A report from the KCHF registry , 2021, PloS one.

[28]  Isla Mackenzie,et al.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial , 2015, The Lancet.

[29]  S. Solomon,et al.  Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction , 2021, European heart journal.

[30]  G. Russo,et al.  Resistant Hypertension, Time‐Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus , 2017, Journal of the American Heart Association.

[31]  L. Lund,et al.  Heart failure with mid-range or mildly reduced ejection fraction , 2021, Nature Reviews Cardiology.